{"title":"Muvz™用于身体活动成人膝关节和腰背支持的随机安慰剂对照剂量反应试验","authors":"Douglas Kalman, Shalini Srivastava, Ajinkya Desale, Manish Devidas Chatte, Rohit J Nalavade, Kshitij Manoj Shah, Sagar Karvir, Surendra Bhasale","doi":"10.2147/DDDT.S486836","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The current study aimed to investigate the dose-response efficacy and safety of Muvz<sup>TM</sup> (E-PR-01, a blend of <i>V. negundo</i> and <i>Z. officinale</i>) in 400 mg (High-dose [HD]) and 200 mg (Low-dose [LD]) of daily dose in physically active adults in 90 days.</p><p><strong>Patients and methods: </strong>The study included 157 adults aged 40-60 having knee/low back joint discomfort. The primary outcome was an enhancement in the overall musculoskeletal health in 90 days. Secondary outcomes included assessing the joint discomfort following physical activity, range of motion, quality of life, and the consumption of rescue medication.</p><p><strong>Results: </strong>E-PR-01 notably enhanced musculoskeletal health in a dose-dependent manner compared to placebo within 30 days (p<0.0001), with effects persisting through day 90 and demonstrated clinically significant difference by 13 and 10 units in the HD and LD groups, respectively. Joint discomfort reduced significantly in both the E-PR-01 groups by day 90 (p<0.0001). Furthermore, both doses of E-PR-01 improved the range of motion of the assessed joint (p<0.05) and enriched participants' overall quality of life (p<0.05) at the end of the study.</p><p><strong>Conclusion: </strong>The study finds E-PR-01 effective for improving overall joint health, with the higher dose showing greater efficacy. These findings align with the earlier studies of E-PR-01 for knee and low back discomfort.</p>","PeriodicalId":11290,"journal":{"name":"Drug Design, Development and Therapy","volume":"19 ","pages":"811-825"},"PeriodicalIF":5.1000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809229/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Randomized Placebo-Controlled Dose-Response Trial of Muvz<sup>™</sup> for Knee and Low-Back Support in Physically Active Adults.\",\"authors\":\"Douglas Kalman, Shalini Srivastava, Ajinkya Desale, Manish Devidas Chatte, Rohit J Nalavade, Kshitij Manoj Shah, Sagar Karvir, Surendra Bhasale\",\"doi\":\"10.2147/DDDT.S486836\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The current study aimed to investigate the dose-response efficacy and safety of Muvz<sup>TM</sup> (E-PR-01, a blend of <i>V. negundo</i> and <i>Z. officinale</i>) in 400 mg (High-dose [HD]) and 200 mg (Low-dose [LD]) of daily dose in physically active adults in 90 days.</p><p><strong>Patients and methods: </strong>The study included 157 adults aged 40-60 having knee/low back joint discomfort. The primary outcome was an enhancement in the overall musculoskeletal health in 90 days. Secondary outcomes included assessing the joint discomfort following physical activity, range of motion, quality of life, and the consumption of rescue medication.</p><p><strong>Results: </strong>E-PR-01 notably enhanced musculoskeletal health in a dose-dependent manner compared to placebo within 30 days (p<0.0001), with effects persisting through day 90 and demonstrated clinically significant difference by 13 and 10 units in the HD and LD groups, respectively. Joint discomfort reduced significantly in both the E-PR-01 groups by day 90 (p<0.0001). Furthermore, both doses of E-PR-01 improved the range of motion of the assessed joint (p<0.05) and enriched participants' overall quality of life (p<0.05) at the end of the study.</p><p><strong>Conclusion: </strong>The study finds E-PR-01 effective for improving overall joint health, with the higher dose showing greater efficacy. These findings align with the earlier studies of E-PR-01 for knee and low back discomfort.</p>\",\"PeriodicalId\":11290,\"journal\":{\"name\":\"Drug Design, Development and Therapy\",\"volume\":\"19 \",\"pages\":\"811-825\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-02-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11809229/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug Design, Development and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2147/DDDT.S486836\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Design, Development and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/DDDT.S486836","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
A Randomized Placebo-Controlled Dose-Response Trial of Muvz™ for Knee and Low-Back Support in Physically Active Adults.
Purpose: The current study aimed to investigate the dose-response efficacy and safety of MuvzTM (E-PR-01, a blend of V. negundo and Z. officinale) in 400 mg (High-dose [HD]) and 200 mg (Low-dose [LD]) of daily dose in physically active adults in 90 days.
Patients and methods: The study included 157 adults aged 40-60 having knee/low back joint discomfort. The primary outcome was an enhancement in the overall musculoskeletal health in 90 days. Secondary outcomes included assessing the joint discomfort following physical activity, range of motion, quality of life, and the consumption of rescue medication.
Results: E-PR-01 notably enhanced musculoskeletal health in a dose-dependent manner compared to placebo within 30 days (p<0.0001), with effects persisting through day 90 and demonstrated clinically significant difference by 13 and 10 units in the HD and LD groups, respectively. Joint discomfort reduced significantly in both the E-PR-01 groups by day 90 (p<0.0001). Furthermore, both doses of E-PR-01 improved the range of motion of the assessed joint (p<0.05) and enriched participants' overall quality of life (p<0.05) at the end of the study.
Conclusion: The study finds E-PR-01 effective for improving overall joint health, with the higher dose showing greater efficacy. These findings align with the earlier studies of E-PR-01 for knee and low back discomfort.
期刊介绍：
Drug Design, Development and Therapy is an international, peer-reviewed, open access journal that spans the spectrum of drug design, discovery and development through to clinical applications.
The journal is characterized by the rapid reporting of high-quality original research, reviews, expert opinions, commentary and clinical studies in all therapeutic areas.
Specific topics covered by the journal include:
Drug target identification and validation
Phenotypic screening and target deconvolution
Biochemical analyses of drug targets and their pathways
New methods or relevant applications in molecular/drug design and computer-aided drug discovery*
Design, synthesis, and biological evaluation of novel biologically active compounds (including diagnostics or chemical probes)
Structural or molecular biological studies elucidating molecular recognition processes
Fragment-based drug discovery
Pharmaceutical/red biotechnology
Isolation, structural characterization, (bio)synthesis, bioengineering and pharmacological evaluation of natural products**
Distribution, pharmacokinetics and metabolic transformations of drugs or biologically active compounds in drug development
Drug delivery and formulation (design and characterization of dosage forms, release mechanisms and in vivo testing)
Preclinical development studies
Translational animal models
Mechanisms of action and signalling pathways
Toxicology
Gene therapy, cell therapy and immunotherapy
Personalized medicine and pharmacogenomics
Clinical drug evaluation
Patient safety and sustained use of medicines.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
